Cited 10 times in

Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer

DC Field Value Language
dc.contributor.author조병철-
dc.date.accessioned2022-12-22T03:38:13Z-
dc.date.available2022-12-22T03:38:13Z-
dc.date.issued2022-09-
dc.identifier.issn1525-7304-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/191926-
dc.description.abstractBackground: Concurrent chemoradiotherapy is a standard therapy for patients with stage III non-small-cell lung cancer (NSCLC). Durvalumab is an approved treatment option following concurrent chemoradiotherapy in the absence of disease progression. The multicenter, phase III, randomized, placebo- and active-controlled, double-blind KEYLYNK-012 study evaluates whether initiation of immunotherapy with pembrolizumab concurrently with chemoradiotherapy, followed by post-chemoradiotherapy pembrolizumab with or without olaparib improves outcomes for participants with stage III NSCLC. (ClinicalTrials.gov: NCT04380636) METHODS: Eligible participants are aged ≥18 years with previously untreated, pathologically confirmed, stages IIIA-C, squamous or nonsquamous NSCLC not suitable for surgery with curative intent. Participants will be randomized 1:1:1 to platinum-doublet chemotherapy plus radiotherapy with pembrolizumab (Groups A and B) or concurrent chemoradiotherapy alone (Group C) for 3 cycles. In the absence of disease progression, participants will receive pembrolizumab plus olaparib placebo (Group A), pembrolizumab plus olaparib (Group B), or durvalumab monotherapy (Group C). Dual primary endpoints are progression-free survival per RECIST version 1.1 by independent central review and overall survival. Results: Enrollment began on July 6, 2020, and is ongoing at approximately 190 sites. Conclusion: KEYLYNK-012 will provide important information on the efficacy and safety of pembrolizumab combined with concurrent chemoradiotherapy and subsequent pembrolizumab with or without olaparib in participants with unresectable stage III NSCLC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfCLINICAL LUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / therapeutic use-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / drug therapy-
dc.subject.MESHChemoradiotherapy-
dc.subject.MESHDisease Progression-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms* / drug therapy-
dc.subject.MESHPhthalazines-
dc.subject.MESHPiperazines-
dc.titleRationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSalma K Jabbour-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorEmilio Bria-
dc.contributor.googleauthorTerufumi Kato-
dc.contributor.googleauthorJaishree Bhosle-
dc.contributor.googleauthorJustin F Gainor-
dc.contributor.googleauthorNoemi Reguart-
dc.contributor.googleauthorLuhua Wang-
dc.contributor.googleauthorDaniel Morgensztern-
dc.contributor.googleauthorYue Shentu-
dc.contributor.googleauthorSung Jin Kim-
dc.contributor.googleauthorFabricio Souza-
dc.contributor.googleauthorMartin Reck-
dc.identifier.doi10.1016/j.cllc.2022.04.003-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ03603-
dc.identifier.eissn1938-0690-
dc.identifier.pmid35618629-
dc.subject.keywordChemotherapy-
dc.subject.keywordImmunotherapy-
dc.subject.keywordNon-small-cell lung cancer-
dc.subject.keywordPARP inhibition-
dc.subject.keywordRadiation therapy-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume23-
dc.citation.number6-
dc.citation.startPagee342-
dc.citation.endPagee346-
dc.identifier.bibliographicCitationCLINICAL LUNG CANCER, Vol.23(6) : e342-e346, 2022-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.